To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advanced/metastatic breast cancer.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer / Rugo, Hope S; Trédan, Olivier; Ro, Jungsil; Morales, Serafin M; Campone, Mario; Musolino, Antonino; Afonso, Noémia; Ferreira, Marta; Park, Kyong Hwa; Cortes, Javier; Tan, Antoinette R; Blum, Joanne L; Eaton, Lamar; Gause, Christine K; Wang, Zhen; Im, Ellie; Mauro, David J; Jones, Mary Beth; Denker, Andrew; Baselga, José. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 165:3(2017), p. 601-609. [10.1007/s10549-017-4375-5]
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Musolino, AntoninoInvestigation
;
2017-01-01
Abstract
To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advanced/metastatic breast cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
